Detection of FUR1 Gene in 5-Flucytosine Resistant Candida Isolates in Vaginal Candidiasis Patients

Gopinathan, S; Janagond, Anand; Agatha, David

doi:10.7860/jcdr/2013/6160.3574

Cited by 6 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this review, resistance to 5-flucytosine increased from 10.56% to 42.01%, even in one article 100% resistance was observed in C. albicans isolated from oropharyngeal candidiasis ( 103 ). Even though, these results differ from some studies ( 106 , 107 ).…”

Section: Discussioncontrasting

confidence: 99%

Antifungal Resistance of Clinical Candida albicans Isolates in Iran: A Systematic Review and Meta-Analysis

Kermani¹,

Armaki²,

Hosseini³

et al. 2023

ijph

View full text Add to dashboard Cite

Background: The present systematic review aimed to investigate the drug susceptibility patterns of Iranian clinical Candida albicans isolates to antifungal drugs (azoles, polyenes, and echinocandins). Methods: Six electronic databases including “PubMed,” “Scopus,” “Web of Science,” “IranDoc”, “SID”, and “Magiran” were searched from May 2000 to June 2021. The susceptibility of 6322 C. albicans strains from 19967 patients against 14 antifungal drugs was evaluated according to CLSI method. Results: The pooled prevalence of antifungal resistance ranged from 0% to 26%. The lowest resistance levels among azoles were observed in luliconazole with a frequency of 0% and voriconazole of 3.94%. Conclusion: Due to the emergence of multi-drug resistant C. albicans, rational drug prescription based on the antifungal stewardship strategy and therapeutic drug monitoring is warranted.

show abstract

Section: Discussioncontrasting

confidence: 99%

Antifungal Resistance of Clinical Candida albicans Isolates in Iran: A Systematic Review and Meta-Analysis

Kermani¹,

Armaki²,

Hosseini³

et al. 2023

ijph

View full text Add to dashboard Cite

show abstract

“…In the fungal cell wall, covalently cross-linked polysaccharides such as b-1, 3-glucan, b-1, 6-glucan, mannose, and chitin are responsible for the structural integrity and shape of the cell (Debono and Gordee 1994). The third class of antifungal agent such as 5-flucytosine inhibits the synthesis of DNA to cause the death of fungal cells (Gopinathan 2013). However, many antifungal peptides isolated in recent years have evolved to act via different mechanisms, and a single peptide is often capable of more than one mode of action, depending on the target cell type.…”

Section: Discussionmentioning

confidence: 99%

Antifungal activity of Brevibacillus laterosporus JX-5 and characterization of its antifungal components

Jiang

Wang

Xiao

et al. 2015

World J Microbiol Biotechnol

View full text Add to dashboard Cite

The establishment of safe and effective methods for controlling fungal disease is an urgent issue in agriculture and forestry. Microbiological control of plant disease is expected to achieve better results than use of chemically derived fungicides. This study aimed to establish Brevibacillus laterosporus JX-5 as a potential microbiological control agent of poplar canker. The bacterium was isolated from the poplar rhizosphere and demonstrated significant growth inhibition of several pathogenic fungi in vitro. The antifungal components of Br. laterosporus JX-5 were isolated and identified. The fermentation broth of Br. laterosporus JX-5 and its main antifungal component, designated as component B, reduced Botryosphaeria dothidea associated canker of the excised poplar branch by 70 and 90%, respectively. Component B is considerably heat-stable, adaptable to a broad pH range, and UV-resistant. It could inhibit Bo. dothidea by permeating the fungal membrane, fracturing the nuclei, damaging the cell wall, and eventually killing the pathogenic fungus. The antifungal activity exhibited by Br. laterosporus JX-5 and its bioactive metabolic products indicate its feasibility as a potential biocontrol agent for plant diseases.

show abstract

“…As a result, 11.1%–58.3% of C. glabrata isolates resistant to echinocandins had cross resistance against fluconazole or other azoles [ 168 , 169 , 172 ], and cross resistance of C. glabrata of echinocandins and amphotericin B have also been reported [ 173 ]. Estimates regarding the percentage of non-susceptible or resistant C. glabrata clinical isolates against four antifungal drugs used in clinical practice, across several geographic regions are: fluconazole, 3.4%–70%; amphotericin B, 2.5%–60%; caspofungin, 1.3%–16.2%, and 5-flucytosine, 0.8%–35%, which are clearly concerning numbers [ 171 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 ]. Additionally, the latest cross-resistance between amphotericin B and azoles or caspofungin in Candida species are increasingly worrying [ 103 , 194 , 195 , 196 , 197 ].…”

Section: Cross And/or Multidrug Resistancementioning

confidence: 99%

Candida glabrata Biofilms: How Far Have We Come?

Rodrigues

Silva

et al. 2017

JoF

105

View full text Add to dashboard Cite

Infections caused by Candida species have been increasing in the last decades and can result in local or systemic infections, with high morbidity and mortality. After Candida albicans, Candida glabrata is one of the most prevalent pathogenic fungi in humans. In addition to the high antifungal drugs resistance and inability to form hyphae or secret hydrolases, C. glabrata retain many virulence factors that contribute to its extreme aggressiveness and result in a low therapeutic response and serious recurrent candidiasis, particularly biofilm formation ability. For their extraordinary organization, especially regarding the complex structure of the matrix, biofilms are very resistant to antifungal treatments. Thus, new approaches to the treatment of C. glabrata’s biofilms are emerging. In this article, the knowledge available on C. glabrata’s resistance will be highlighted, with a special focus on biofilms, as well as new therapeutic alternatives to control them.

show abstract

Detection of FUR1 Gene in 5-Flucytosine Resistant Candida Isolates in Vaginal Candidiasis Patients

Cited by 6 publications

References 12 publications

Antifungal Resistance of Clinical Candida albicans Isolates in Iran: A Systematic Review and Meta-Analysis

Antifungal Resistance of Clinical Candida albicans Isolates in Iran: A Systematic Review and Meta-Analysis

Antifungal activity of Brevibacillus laterosporus JX-5 and characterization of its antifungal components

Candida glabrata Biofilms: How Far Have We Come?

Contact Info

Product

Resources

About